Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bolis

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Journal of Medicinal Chemistry|October 1, 1987
Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bondG Bolis, A K Fung, J Greer, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1997
A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancerG Bolis, G Scarfone, F Zanaboni, et al.
Journal of Medicinal Chemistry|February 1, 1988
Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogenH L Sham, G Bolis, H H Stein, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2002
Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer GroupF H van Wijk, C Lhommé, G Bolis, et al.
Journal of Medicinal Chemistry|March 1, 1988
New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 siteJ R Luly, G Bolis, N BaMaung, et al.
Cancer|October 1, 1977
Lymphangiography in patients with ovarian epithelial cancer: an evaluation of 289 consecutive casesR Musumeci, A Banfi, G Bolis, et al.
Journal of the National Cancer Institute|October 4, 1995
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibodyS Canevari, G Stoter, F Arienti, et al.
Journal of Medicinal Chemistry|December 1, 1988
Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stabilityJ J Plattner, P A Marcotte, H D Kleinert, et al.
Seminars in Oncology|February 1, 1994
High-dose intensity regimens with epirubicin in ovarian cancerJ B Vermorken, G Bolis, R E van Rijswijk, et al.
European Journal of Gynaecological Oncology|January 1, 1995
High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experienceJ B Vermorken, A Kobierska, M E van der Burg, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Journal of Medicinal Chemistry|October 1, 1987
Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bondG Bolis, A K Fung, J Greer, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1997
A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancerG Bolis, G Scarfone, F Zanaboni, et al.
Journal of Medicinal Chemistry|February 1, 1988
Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogenH L Sham, G Bolis, H H Stein, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2002
Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer GroupF H van Wijk, C Lhommé, G Bolis, et al.
Journal of Medicinal Chemistry|March 1, 1988
New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 siteJ R Luly, G Bolis, N BaMaung, et al.
Cancer|October 1, 1977
Lymphangiography in patients with ovarian epithelial cancer: an evaluation of 289 consecutive casesR Musumeci, A Banfi, G Bolis, et al.
Journal of the National Cancer Institute|October 4, 1995
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibodyS Canevari, G Stoter, F Arienti, et al.
Journal of Medicinal Chemistry|December 1, 1988
Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stabilityJ J Plattner, P A Marcotte, H D Kleinert, et al.
Seminars in Oncology|February 1, 1994
High-dose intensity regimens with epirubicin in ovarian cancerJ B Vermorken, G Bolis, R E van Rijswijk, et al.
European Journal of Gynaecological Oncology|January 1, 1995
High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experienceJ B Vermorken, A Kobierska, M E van der Burg, et al.
Pageof 13